| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
No specific biological target is associated with Polyoxyl 40 stearate as it functions as a pharmaceutical excipient rather than a pharmacologically active ingredient. Its primary role is as a surfactant and emulsifying agent in drug formulations. It reduces surface tension between immiscible phases, facilitating the formation of stable emulsions and improving the solubility and bioavailability of poorly soluble drugs.
|
|---|---|
| ln Vitro |
As an excipient, Polyoxyl 40 stearate does not exert direct pharmacological activity in cell-based assays. Its in vitro function is evaluated based on its physicochemical properties, including emulsification efficiency, solubilization capacity, and compatibility with active pharmaceutical ingredients. It is used in cell culture media and formulation development to enhance drug solubility and stability. The compound shows good dispersibility in water and is soluble in toluene, acetone, ether, and ethanol.
|
| ln Vivo |
Polyoxyl 40 stearate is not designed for direct in vivo pharmacological activity but is used as a formulation component in orally administered drug products. It functions as an absorption enhancer and emulsifier, improving the oral bioavailability of poorly soluble drugs by facilitating micelle formation and increasing drug dissolution. Its safety and efficacy as an excipient have been well established in numerous pharmaceutical products.
|
| Enzyme Assay |
No specific receptor binding assays are applicable as Polyoxyl 40 stearate functions as an excipient. Its physical properties are characterized by standard pharmacopoeial methods: congealing temperature between 37-47°C, acid value not more than 2, hydroxyl value between 25-40. Saponification value: 23-33 mgKOH/g; moisture ≤1.0%; pH (1% aqueous solution): 5.0-7.0; HLB value: 16.5-17.5. These parameters ensure batch-to-batch consistency and quality for pharmaceutical use.
|
| Cell Assay |
Cell-based studies involving Polyoxyl 40 stearate typically focus on its effects as a formulation excipient rather than direct cellular activity. Cytotoxicity assays (MTT, LDH release) are performed to assess biocompatibility in various cell lines, including Caco-2 (intestinal epithelial), HepG2 (hepatic), and primary cell cultures. Cells are exposed to varying concentrations of the compound (typically 0.001-1% w/v) for 24-72 hours. Membrane integrity and cell viability are evaluated. Permeability studies using Caco-2 cell monolayers assess its effect on drug transport and paracellular permeability.
|
| Animal Protocol |
In vivo studies with Polyoxyl 40 stearate are typically conducted as part of toxicology and safety evaluation for drug formulations. Animal models (rats, dogs) are administered the compound orally or intravenously at doses reflecting intended human exposure levels. Parameters assessed include body weight, food consumption, clinical observations, hematology, clinical chemistry, urinalysis, and gross necropsy with histopathological examination of major organs. Studies follow OECD or ICH guidelines for excipient safety evaluation. Pharmacokinetic studies assess absorption, distribution, metabolism, and excretion of the formulation.
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
These esters are hydrolyzed in the intestine. Fatty acids are absorbed and metabolized; at least the shorter polyoxyethylene residues are also absorbed, but they are excreted in urine in an unchanged form (metabolized to oxalic acid is not detected in the human body). As a pharmaceutical excipient, Polyoxyl 40 stearate is not intended to be systemically absorbed. It is primarily used in oral and topical formulations. The compound is water-soluble and readily dispersible. In the gastrointestinal tract, it may be partially hydrolyzed to stearic acid and PEG, which are metabolized via normal fatty acid oxidation pathways. The PEG component is excreted renally. Its pharmacokinetic profile is well characterized through extensive use in approved pharmaceutical products. |
| Toxicity/Toxicokinetics |
Interactions
MYRI 32 increased the gastrointestinal absorption of gentamicin after oral administration in rats. In female rats, the sensitivity of feeding tests to detect its carcinogenicity was increased when administered at an earlier age with low doses of 7,12-dimethylbenzo[a]anthracene and a high-fat diet containing 1% polyoxyethylene monostearate. Polyoxyl 40 stearate is widely recognized as safe for use in pharmaceutical and cosmetic applications. It is listed in the FDA Inactive Ingredients Database and is included in the USP-NF monograph. Acute oral toxicity is low (LD50 > 5 g/kg in rats). It is not considered a skin sensitizer or irritant at typical use concentrations. The compound has a long history of safe use as a food additive and pharmaceutical excipient. No genotoxicity or carcinogenicity concerns have been identified at intended use levels. |
| References |
|
| Additional Infomation |
Polyoxyl 40 stearate is an octadecanoate composed of 8-40 repeating ethylene oxide units. It is a common ingredient in cosmetics and beauty products, primarily used as a surfactant and emulsifier. It is a nonionic surfactant, emulsifier, and food emulsifier. It is a hydroxyl polyether and octadecanoate.
See also: PEG-10 stearate (note moved to); PEG-150 stearate (note moved to); PEG-40 stearate (note moved to)...See more... Polyoxyl 40 stearate is also known as polyethylene glycol monostearate and is available in various grades (Type II, NF). It is used in a wide range of pharmaceutical products including tablets, capsules, creams, ointments, and intravenous formulations as an emulsifier, solubilizer, and wetting agent. The compound is manufactured under cGMP conditions in FDA-registered facilities. It complies with USP-NF standards and is approved for use in multiple regulatory jurisdictions. |
| Molecular Formula |
C20H40O3
|
|---|---|
| Molecular Weight |
328.5298
|
| Exact Mass |
328.297
|
| CAS # |
9004-99-3
|
| Related CAS # |
Polyoxyethylene stearate;9004-99-3
|
| PubChem CID |
24762
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
438.4±18.0 °C at 760 mmHg
|
| Melting Point |
MP: 30-34 °C /POLYETHYLENE GLYCOL 400 MONOSTEARATE USP XVI/
; 60.00 to 61.00 °C. @ 760.00 mm Hg
|
| Flash Point |
164.6±14.0 °C
|
| Vapour Pressure |
0.0±2.4 mmHg at 25°C
|
| Index of Refraction |
1.457
|
| LogP |
7.85
|
| tPSA |
46.53
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
23
|
| Complexity |
241
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCCCC(=O)OCCO
|
| InChi Key |
RFVNOJDQRGSOEL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H40O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-20(22)23-19-18-21/h21H,2-19H2,1H3
|
| Chemical Name |
2-hydroxyethyl octadecanoate
|
| Synonyms |
S 1012; S 1004; Polyoxyl 40 stearate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0439 mL | 15.2193 mL | 30.4386 mL | |
| 5 mM | 0.6088 mL | 3.0439 mL | 6.0877 mL | |
| 10 mM | 0.3044 mL | 1.5219 mL | 3.0439 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.